Format

Send to

Choose Destination
J Ultrasound Med. 2015 Aug;34(8):1489-99. doi: 10.7863/ultra.34.8.1489.

Contrast-Enhanced Sonography for Monitoring Neoadjuvant Chemotherapy in Soft Tissue Sarcomas.

Author information

1
Departments of Radiology (M.G., B.D., D.H.H., E.G.G., V.A.D.) and Medicine (J.S.H.), University of Southern California Keck School of Medicine, Los Angeles, California USA. mittul.gulati@med.usc.edu.
2
Departments of Radiology (M.G., B.D., D.H.H., E.G.G., V.A.D.) and Medicine (J.S.H.), University of Southern California Keck School of Medicine, Los Angeles, California USA.

Abstract

Neoadjuvant chemotherapy is a mainstay in treating soft tissue sarcomas. Soft tissue sarcomas can show an increase in size and central necrosis, with a decrease in the viable tumor, as an initial response to neoadjuvant chemotherapy. Thus, the maximum tumor diameter may not reliably assess the response to this therapy. Contrast-enhanced sonography may address this limitation. We evaluated 4 patients with soft tissue sarcomas by contrast-enhanced sonography, performed concomitantly with conventional imaging (computed tomography, magnetic resonance imaging, or positron emission tomography). Quantitative analysis was also performed on 1 sarcoma. A viable, enhancing tumor versus tumor necrosis was nearly identical on contrast-enhanced sonography and conventional imaging. Preliminary results demonstrate potential for contrast-enhanced sonographic monitoring of soft tissue sarcomas during neoadjuvant chemotherapy.

KEYWORDS:

contrast-enhanced sonography; neoadjuvant chemotherapy; quantitative analysis; soft tissue sarcoma

PMID:
26206837
DOI:
10.7863/ultra.34.8.1489
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center